DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

Docket		Date Filed	2011-11-03
Court	District Court, D. Delaware	Date Terminated	2014-09-17
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ACTAVIS INC.; ACTAVIS SOUTH ATLANTIC LLC; ACTAVIS, INC.; LTS LOHMANN THERAPIE-SYSTEME AG; NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORPORATION; PAR PHARMACEUTICAL INC.; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC.
Patents	6,316,023; 6,335,031; 6,699,498
Attorneys	Andrea M. Houston; C. Nicole Gifford; Daniel G. Brown; Daniel M. Silver; Dominick T. Gattuso; Erika R. Caesar; Erin A. Thomson; Gina R. Gencarelli; Jaclyn C. Levy; James L. Higgins; Jennifer Koh; Katharine Crawford Lester; Melanie K. Sharp; Michael P. Kelly; Michelle R. Ma; Robert M. Vrana; Stephen M. Hash; Steven J. Fineman
Firms	Ballard Spahr LLP; Friedlander & Gorris, P.A.; Proctor Heyman LLP; Richards, Layton & Finger, PA; Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-11-01	319		is not an oxidizing environment L`§.S poteet 6,699,498 (the “L'l`S petent’”‘), assigned to ]§*.§e…et limited States patents 6,3 35. l(“°OB] patent ) and 6 ,.3]6 {}23 (_ “’GZB patent ’) {_e~t)§leetivety…far below the threshold set by the LTS patent 'i`hc patents in colt also z‘ecognize that “co'l.npound…Composition” Ciaims {3 and 7 of the ’031 patent and 2 and 7 of the . ’{323 patent) I.~ ’}"here is No Evidenee…quot;’ C1aims (3 and 7 0'1" 1110 ’{)3 1 patent and 2 and 7 of the "023 paf‘enf) ........	External link to document
2014-06-18	40		detecting peroxides. U.S. Patent No. 6,699,498, 2:58- 62 ("the '498 patent") ("The peroxide…the '023 patent") (collectively, "the patents in suit"). Both patents share the same…that the patent examiner for the '023 and '031 patents considered both the '807 patent and U.S…alleging infringement of U.S. Patent Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("…16, and 18 of the '031 patent and claims 2 and 7 of the '023 patent. Watson counters that the	External link to document
2014-06-18	414		detecting peroxides. U.S. Patent No. 6,699,498, 2:58- 62 ("the '498 patent") ("The peroxide…the '023 patent") (collectively, "the patents in suit"). Both patents share the same…that the patent examiner for the '023 and '031 patents considered both the '807 patent and U.S…alleging infringement of U.S. Patent Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("…16, and 18 of the '031 patent and claims 2 and 7 of the '023 patent. Watson counters that the	External link to document
2014-08-29	426		infringement of U.S. Patents Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("the '…#39;023 patent") (collectively, "the patents in suit"). Both patents share the same specification…Par's ANDA products infringe claim 7 of the '031 patent. Par should submit an agreed upon form of final…). 3 Novartis listed the '031 and '023 patents in the Food and Drug Administration's "…citations to the specification refer to the '031 patent. 3 Unless otherwise noted, all citations to the	External link to document
2014-09-17	429		not infringe U.S. Patent No. 6,316,023 ("the '023 patent"); and it is further …any valid claim of U.S. Patent No. 6,335,031 ("the '031 patent"); and whether those… 16 and 18 of the '031 patent and claims 2 and 7 of the '023 patent are not obvious; … No. 202339, do not infringe the '031 patent; and it is further ORDERED AND …ANDA No. 202339, does not infringe the '031 patent; and it is further ORDERED AND	External link to document